Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial-2 (MINT-2)"
Summary
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate. In this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved/at-risk regional neck nodes. Based on the pathology report, patients will be assigned to: * Arm 1 (de-POACRT-42 Gy) * Arm 2A (de-POART-42 Gy) * Arm 2B (de-POART-37.8 Gy) * Arm 2C (de-POACRT-30 Gy). All patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.
Arms & interventions
- RadiationRadiation therapy
IMRT or IMPT
- DrugCisplatin
Dose of 100 mg/m\^2 IVPB over 60 minutes
- ProcedureSurgery
Standard of care
Outcome measures
Primary
Recurrence rate
Time frame: At 2 years
Secondary
Percent weight loss
Time frame: From start of radiation therapy to completion of radiation therapy (estimated to be 6 weeks)
Proportion of patients undergoing PEG tube placement
Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)
Duration of need for an indwelling PEG tube
Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)
Proportion of patients taking narcotic
Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)
Number of participants with adverse events
Time frame: From start of surgery through 24-month follow-up visit (estimated to be 2 years and 10 weeks)
Mean change in serum creatinine during radiation therapy
Time frame: From start of radiation therapy to completion of radiation therapy (estimated to be 6 weeks)
Progression-free survival (PFS)
Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)
Overall survival (OS)
Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)
Eligibility criteria
Study locations (3)
Washington University School of Medicine
St Louis, Missouri, 63110
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58102
Sanford Cancer Center
Sioux Falls, South Dakota, 57104